Linifanib (GMP)
Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells[1].
Product Specifications
CAS Number
[796967-16-3]
Product Name Alternative
ABT-869 (GMP) ; AL-39324 (GMP)
UNSPSC
12352005
Hazard Statement
H361, H372, H410
Target
PDGFR; VEGFR
Type
GMP Small Molecules
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/linifanib-gmp.html
Purity
99.9
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC=C(C2=C3C(N)=NNC3=CC=C2)C=C1)NC4=C(C=CC(C)=C4)F
Molecular Formula
C21H18FN5O
Molecular Weight
375.40
Precautions
H361, H372, H410
References & Citations
[1]Guan J, et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022 May;605 (7909) :325-331.
Shipping Conditions
Blue Ice
Storage Conditions
Keep sealed and protect from light, store at 2-8°C
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
